-- Presentation to be webcast on www.exelixis.com
--
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 3, 2016--
Exelixis, Inc. (NASDAQ:EXEL) today announced that the company and its
partner Ipsen will jointly host a live investor and media briefing at
the European Society for Medical Oncology (ESMO) 2016 Congress. The
event will be held on Monday, October 10, 2016, with the program
beginning at 19:00 CEST (local Copenhagen time) / 1:00 p.m. EDT / 10:00
a.m. PDT following on-site registration starting at 18:30 CEST.
During the briefing, Exelixis and Ipsen management and invited guests
will discuss and provide context for clinical data for cabozantinib
presented at the ESMO 2016 Congress. Key topics will include CABOSUN,
the randomized phase 2 trial of cabozantinib compared with sunitinib in
patients with previously untreated advanced renal cell carcinoma, which
will be the subject of a late-breaking oral presentation during ESMO’s
Presidential Symposium 3 earlier in the day. Presenters will also review
data from the ongoing phase 1b trial evaluating the combination of
cabozantinib and nivolumab in patients with genitourinary tumors.
The briefing will also be webcast live and available via conference call
starting at 19:00 CEST / 1:00 p.m. EDT / 10 a.m. PDT on Monday, October
10. To access the webcast link, log onto www.exelixis.com
and proceed to the Event Calendar page under Investors & Media. Please
connect to the company’s website at least 15 minutes prior to the
webcast to ensure adequate time for any software download that may be
required to listen to the event. To participate by phone, please dial
855-299-5224 (domestic) or 631-267-4890 (international/toll dial) and
use passcode 234-026-024. Please see the Event Calendar page for details
on replay options once available.
About Exelixis
Exelixis, Inc. (Nasdaq: EXEL) is a biopharmaceutical company committed
to the discovery, development and commercialization of new medicines
with the potential to improve care and outcomes for people with cancer.
Since its founding in 1994, three medicines discovered at Exelixis have
progressed through clinical development to receive regulatory approval.
Currently, Exelixis is focused on advancing cabozantinib, an inhibitor
of multiple tyrosine kinases including MET, AXL and VEGF receptors,
which has shown clinical anti-tumor activity in more than 20 forms of
cancer and is the subject of a broad clinical development program. Two
separate formulations of cabozantinib have received regulatory approval
to treat certain forms of kidney and thyroid cancer and are marketed for
those purposes as CABOMETYX™ tablets (U.S. and EU) and COMETRIQ®
capsules (U.S. and EU), respectively. Another Exelixis-discovered
compound, COTELLIC® (cobimetinib), a selective inhibitor of
MEK, has been approved in major territories including the United States
and European Union, and is being evaluated for further potential
indications by Roche and Genentech (a member of the Roche Group) under a
collaboration with Exelixis. For more information on Exelixis, please
visit www.exelixis.com
or follow @ExelixisInc on Twitter.
Exelixis, the Exelixis logo, COMETRIQ and COTELLIC are registered
U.S. trademarks, and CABOMETYX is a U.S. trademark.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161003006414/en/
Source: Exelixis, Inc.
Exelixis, Inc.
Susan Hubbard, 650-837-8194
Investor
Relations and Public Affairs
shubbard@exelixis.com
or
For
Exelixis, Inc.
Hal Mackins, 415-994-0040
hal@torchcomllc.com
